KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Leerink Partnrs lowered their Q3 2024 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, February 13th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings per share of ($0.69) for the quarter, down from […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Research analysts at Leerink Partnrs boosted their Q2 2024 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Thursday, September 7th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will earn ($0.66) per share for the quarter, up from […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) – Equities research analysts at Cantor Fitzgerald lifted their FY2023 earnings per share estimates for KalVista Pharmaceuticals in a research note issued to investors on Tuesday, April 11th. Cantor Fitzgerald analyst C. Duncan now forecasts that the specialty pharmaceutical company will post earnings of ($3.56) per share for […]
Equities analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KalVista Pharmaceuticals’ earnings, with estimates ranging from ($1.19) to ($0.81). KalVista Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last […]